| ²é¿´: 1429 | »Ø¸´: 7 | |||
[½»Á÷]
ÇóÖú¹ØÓÚÀûÒæ³åÍ»ÎÊÌ⣡¼±
|
|||
|
ÒòΪÎÄÕÂÖÐÁгöÁËÒ»¸ö¸øÎÒÃÇÌṩԲÄÁϵĹ«Ë¾µÄÈËQZ£¬ËùÒÔPLOS ONEдÁËEMAILÒªÇóÌṩÀûÒæ³åÍ»ÉùÃ÷£¬ÎÒÃÇÐ޻غóÓÖÀ´ÐÅ¡£ÏÖÔÚÏë°ÑQZÁÐÈëÖÂлÓÖÅÂÔÓ־ѯÎÊ×÷Õß±¾ÈËͬÒⱻɾ³ýÂð£¿ÁíÍ⣬ÔÚ²ÄÁÏÒ»ÏîÖУ¬ÎÒÃǶ¼Ð´³ÉÁË´Ó²úµØ¹«Ë¾¹ºÂòµÄ£¬Íü¼Çд³ÉQZÀ¡ÔùµÄÁË¡£Âé·³ÔÚ´ËÇóÖú¸÷룬ÈçºÎÈ¥»Ø´ð¡£ÏÈл¹ýÁË£¡ Dear Dr **, Thank you for submitting your manuscript entitled "**" to PLoS ONE. Your manuscript files have been checked in house but before we can proceed, we need you to address the following issues: 1) Thank you for submitting your revised paper, and for informing us of the following in your cover letter: "All authors declare that there are no conflicts of interest and approved to submit to your journal. We also declare that there are no conflicts of interests or financial disclosure, along with employment, consultancy, patents, products in development or marketed products with ** Pharmaceutical Industry Research Institute Co. Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials." We have reviewed this information and would like to suggest the following statements. Competing interest: "QZ is an employee of ** Pharmaceutical Industry Research Institute Co. Ltd. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials." Financial disclosure: "This work is supported by the National Natural Science Foundation of China (No: **). ** Pharmaceutical Industry Research Institute Co. Ltd., provided support in the form of a salary for author QZ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ¡®author contributions¡¯ section.¡± Please respond by via the cover letter with your approval of the revised statements, if pertinent, alternatively please amend accordingly. We will change the online submission form on your behalf. [ Last edited by ph3719 on 2014-2-26 at 21:56 ] |
» ²ÂÄãϲ»¶
²ÄÁÏ¿¼ÑÐÇóµ÷¼Á×Ü·Ö280
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ10È˻ظ´
Çóµ÷¼Áµ½²ÄÁÏ
ÒѾÓÐ3È˻ظ´
»¯¹¤Çóµ÷¼Á£¡
ÒѾÓÐ9È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁϹ¤³Ì310ר˶µ÷¼Á
ÒѾÓÐ15È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ16È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
µ°°×ŨËõºó³öÎÊÌâÁË£¬¼±ÇóÖú
ÒѾÓÐ7È˻ظ´
¼±£¡£¡£¡ÇóÖú £ºCHEMICAL ENGINEERING JOURNAL Ïà¹ØµÄͶ¸åÎÊÌâ
ÒѾÓÐ8È˻ظ´
¼±ÎÊһϣ¬ÊÕµ½±à¼²¿µÄÓʼþ£¬ÕâÊÇʲôÒâ˼£¿
ÒѾÓÐ11È˻ظ´
ÇóÖú¹ØÓÚ¼ÓÄôóǩ֤work permitµÄÎÊÌ⣡£¡£¡¼±£¡£¡~
ÒѾÓÐ5È˻ظ´
¼± nano letterͶ¸åϵͳ״̬ÎÊÌâÇóÖú
ÒѾÓÐ4È˻ظ´
ÇóÖú¹ØÓÚÖÐÎÄ¿ÆÑ§Í¨±¨Í¶¸åµÄÎÊÌ⣬¼±
ÒѾÓÐ19È˻ظ´
ÇóÖúÈçºÎÓò´ËÉ·½³Ì½â¼¸ºÎµç»¯Ñ§ÎÊÌ⣬¼±¼±¼±£¡£¡£¡
ÒѾÓÐ3È˻ظ´
WPSµÄÒ»¸öÎÊÌ⣡¼±£¡
ÒѾÓÐ10È˻ظ´
½ô¼±ÇóÖú£º¹ØÓÚ·É»úƱ·¢Æ±Ì§Í·µÄÎÊÌâ
ÒѾÓÐ9È˻ظ´
¼±~¹ØÓÚ²¨º¯Êý¶Ô³ÆÐÔµÄÎÊÌâÇóÖú
ÒѾÓÐ10È˻ظ´
Çó½ÌInternational journal of pharmaceutics Ͷ¸åµÄ¼¸¸öÎÊÌ⣡¼±~~~лл
ÒѾÓÐ5È˻ظ´
ÇóÖú£¬Í¶¸åÒªÇóÖеıí¸ñÎÊÌ⣬ͷ´ó£¬¼±£¬Ð»Ð»°ïÖú£¡
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿×Éѯһ¸ö¹ØÓÚDS-2019µÄÎÊÌ⣨¼±ÎÊ£©
ÒѾÓÐ10È˻ظ´
¡¾ÇóÖú¡¿£Å£Ä£Ã¡¢£Î£È£ÓÎÊÌâ,·Ç³£¼±£¬Ð»Ð»
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚÖÐҩѪÇåÒ©ÎﻯѧµÄһЩÎÊÌ⣬¼±£¡
ÒѾÓÐ17È˻ظ´
¡¾ÇóÖú¡¿¡¾ÇóÖú¡¿Êýѧ½¨Ä£ÎÊÌ⣬¡¶Ê³ÌþͲÍÎÊÌâ¡·¡£¡£¡£¼±£¡£¡£¡£¡£¡
ÒѾÓÐ11È˻ظ´
ÇóÖúѪ¹ÜÄÚÆ¤Ï¸°ûÅàÑøÎÊÌ⣨¼±£©
ÒѾÓÐ6È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
°²»Õʦ·¶´óѧÓлú»¯Ñ§×¨Òµµ÷¼Á
+1/281
½Î÷¿Æ¼¼Ê¦·¶´óѧÎïÀí»¯Ñ§¿ÎÌâ×éÕÐÉú£¬07,08¶¼¿É£¬»¹ÓÐÃû¶î
+1/93
»¶ÓÓÅÐ㿼Éúµ÷¼Á½Î÷Àí¹¤´óѧϡÍÁѧԺ
+1/86
½ËÕº£Ñó´óѧ+»·¾³Ó뻯ѧ¹¤³ÌѧԺ+¿ÎÌâ×éÕе÷¼ÁÉú+µÚÒ»Åúµ÷¼Á
+2/52
ÉϺ£Ó¦Óü¼Êõ´óѧÁõÃô¿ÎÌâ×é ÕÐÉúµ÷¼ÁÉú---»¶Ó»¯Ñ§£¬»¯¹¤£¬²ÄÁÏ£¬ÉúÎïµÈÏà½ü·½Ïò
+2/42
°²»Õ¹¤Òµ´óѧ¹¤³ÌÑо¿Ôº½ÓÊܵ÷¼Á
+1/39
¹þ¶û±õ¹¤Òµ´óѧ»¯¹¤Ñ§ÔºÖжíÁªºÏ°ìѧ˶ʿÉúÕÐÉú
+1/22
¿¹²¡¶¾ÐÔ´«È¾²¡´´ÐÂÒ©ÎïÈ«¹úÖØµãʵÑéÊÒ¡ª½ÓÊÕ»¯Ñ§¡¢ÉúÎҩѧ¡¢ÉúÎïÓëÒ½Ò©µ÷¼Á¿¼Éú
+1/22
¸£½¨Å©ÁÖ´óѧ×Ê»·Ñ§ÔºÀîÏãÕæ-Ò¦Ãô½Ü½ÌÊÚ¿ÎÌâ×éÕÐÊÕ˶ʿµ÷¼ÁÉú
+1/10
Ìì½ò¿Æ¼¼´óѧ¾¹ÜѧԺҦΰ½ÌÊÚÍŶӣºÖªÊ¶Éú̬Ñо¿ÖÐÐĽÓÊܹÜÀí¿ÆÑ§Ó빤³Ì2026µ÷¼ÁÉú
+1/9
Î人·ÄÖ¯´óѧÕÐÊÕ»¯Ñ§»¯¹¤ÀàºÍ²ÄÁÏÀàÑо¿Éúµ÷¼ÁÉúÈô¸ÉÃû
+1/8
¼ªÁÖ¹¤³Ì¼¼Êõʦ·¶Ñ§Ôº ²ÄÁÏÓ뻯¹¤ £¨0856£© ÕÐÊÕµ÷¼Á
+1/6
²³º£´óѧ²ÄÁÏÓë»·¾³¹¤³ÌѧԺ·¢¹â¼°Í¸Ã÷ÌմɲÄÁÏ¡¢µØ¾ÛÎïÎü²¨»ìÄýÍÁ·½Ïò½ÓÊÕÑо¿Éúµ÷¼Á
+1/5
¹þ¹¤³ÌÑĮ̀Ժ²Ä»¯×¨Òµ2026µ÷¼ÁÐÅÏ¢
+1/4
º½¿Õ¹¤³Ì363·ÖÇóµ÷¼Á
+1/4
»¶Ó¹ã´ó¿¼Éúµ÷¼Áµ½Î÷°²¹¤³Ì´óѧ»·¾³Ó뻯ѧ¹¤³ÌѧԺ
+1/3
¹þ¶û±õ¹¤³Ì´óѧ¶¯Á¦Ñ§ÔºÕÔ½¨»ÔÍŶÓÕÐÊÕ2026²©Ê¿Ñо¿Éú
+1/3
¡¾#ÉϺ£µ÷¼Á¼±Â¼#¡¿ÄܽÓÊÜ985ÁªºÏÅàÑøµÄËÙÀ´£¡´øÄã·¢Ò»ÇøÎÄÕ£¡
+1/3
ÆëÆë¹þ¶û´óѧÀîÀò¿ÎÌâ×é³ÏÕÐ2026¼¶¿¼Ñе÷¼ÁÉú£¨Ñ§Ë¶ºÍר˶£©
+1/2
½Î÷ũҵ´óѧ¶¯¿ÆÔº¡°À¥³æ-¹²Éú¾úÐͬ½ø»¯¡±·½ÏòÕÐÊÕµ÷¼ÁÑо¿Éú
+1/1
8Â¥2014-02-27 09:20:50
¼òµ¥»Ø¸´
yingying15882Â¥
2014-02-26 23:15
»Ø¸´
ph3719(½ð±Ò+1): лл²ÎÓë
nowitzki_ci3Â¥
2014-02-26 23:38
»Ø¸´
ph3719(½ð±Ò+1): лл²ÎÓë
×£¸£ [ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]
wangyillang4Â¥
2014-02-26 23:58
»Ø¸´
ph3719(½ð±Ò+1): лл²ÎÓë

´÷¸Ö¿øµÄÖíÍ·5Â¥
2014-02-27 07:32
»Ø¸´
ph3719(½ð±Ò+1): лл²ÎÓë
¡£ [ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]
159413916676Â¥
2014-02-27 08:45
»Ø¸´
ph3719(½ð±Ò+1): лл²ÎÓë
lwycau7Â¥
2014-02-27 09:18
»Ø¸´














»Ø¸´´ËÂ¥